Technical Analysis for XBIO - Xenetic Biosciences, Inc.

Grade Last Price % Change Price Change
B 4.25 -2.30% -0.10
XBIO closed down 2.3 percent on Monday, March 18, 2024, on 74 percent of normal volume.
Earnings due: Mar 21
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
180 Bullish Setup Bullish Swing Setup -2.30%
Up 3 Days in a Row Strength -2.30%
Upper Bollinger Band Walk Strength 1.55%
Gapped Up Strength 1.55%
Upper Bollinger Band Touch Strength 1.55%
Golden Cross Bullish 1.92%
Upper Bollinger Band Touch Strength 1.92%
Calm After Storm Range Contraction 6.25%

   Recent Intraday Alerts

Alert Time
20 DMA Support about 12 hours ago
10 DMA Support about 12 hours ago
Down 5% about 16 hours ago
Down 3% about 16 hours ago
Fell Below Previous Day's Low about 16 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Xenetic Biosciences, Inc. Description

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Pharmaceutical Products FDA Acute Myeloid Leukemia Kidney Disease Dialysis Anemia Chronic Kidney Disease Drug Therapies Platform Technologies Endometrial Cancer Refractory Acute Myeloid Leukemia Erythropoietin Growth Factors

Is XBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.97
52 Week Low 2.55
Average Volume 5,189
200-Day Moving Average 3.77
50-Day Moving Average 3.80
20-Day Moving Average 4.05
10-Day Moving Average 4.16
Average True Range 0.29
RSI (14) 56.52
ADX 10.39
+DI 20.56
-DI 20.40
Chandelier Exit (Long, 3 ATRs) 3.63
Chandelier Exit (Short, 3 ATRs) 4.41
Upper Bollinger Bands 4.44
Lower Bollinger Band 3.65
Percent B (%b) 0.76
BandWidth 19.42
MACD Line 0.13
MACD Signal Line 0.12
MACD Histogram 0.0101
Fundamentals Value
Market Cap 6.55 Million
Num Shares 1.54 Million
EPS -2.90
Price-to-Earnings (P/E) Ratio -1.47
Price-to-Sales 2.53
Price-to-Book 0.55
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.75
Resistance 3 (R3) 4.73 4.54 4.66
Resistance 2 (R2) 4.54 4.42 4.55 4.63
Resistance 1 (R1) 4.40 4.34 4.31 4.42 4.61
Pivot Point 4.21 4.21 4.17 4.22 4.21
Support 1 (S1) 4.07 4.09 3.98 4.09 3.89
Support 2 (S2) 3.88 4.01 3.89 3.87
Support 3 (S3) 3.74 3.88 3.84
Support 4 (S4) 3.76